After growth hormone stimulation: The Peptide Brand
A brand suggests a lasting mark. The peptide studies raise a practical question: what remains when stimulation ends?
Tesamorelin after discontinuation
The most revealing part of a tesamorelin study came when treatment stopped. In the 52-week program in adults with HIV and abdominal fat accumulation, visceral fat reduction was sustained at 18% during continued treatment. After discontinuation, visceral fat accumulated again.
I had stamped the successful fat-reduction trial “change achieved.” The withdrawal result reopened that file. A visible response can depend on continued stimulation; whether it persists is a separate, practical question. I value the fading effect as much as the initial change.
Tesamorelin has an approved prescription use for excess abdominal fat in adults with HIV-associated lipodystrophy. That specific use gives this discussion a firm starting point. The same result cannot establish general weight loss or an anti-aging effect. It does, however, put a useful question to the rest of the growth hormone peptide literature: how long does the signal last, and what happens to the thing it changed?
Growth hormone peptides and the pituitary
Growth hormone, usually shortened to GH, comes from the pituitary in pulses. The hypothalamus sends an upstream signal called growth hormone-releasing hormone, or GHRH. Sermorelin, tesamorelin and CJC-1295 imitate that signal; ipamorelin reaches the pituitary through the ghrelin receptor. The review of GHRH and its analogues describes a system with several inputs and feedback controls.
The cells receiving the GHRH message are somatotrophs—the pituitary’s growth-hormone-producing cells. GH then stimulates production of insulin-like growth factor 1, or IGF-1, including in the liver. In GH axis research, a rise in those blood measurements establishes a response. Its duration and its consequences still have to be measured.
The adjective “long acting” gets generous credit. I want the outcome beside it before granting that credit. CJC-1295 makes it possible to examine the attraction closely. Tesamorelin makes it possible to ask a different question, about a tissue change after treatment ends.
Peptide exposure and response
Tesamorelin starts with the strongest clinical outcome record here. Its withdrawal findings place an asterisk beside the appealing idea of a lasting reset: the observed visceral-fat change depended on continued treatment in the studied HIV population.
CJC-1295 offers unusually persistent exposure. Early human studies measured GH and IGF-1 elevations extending across days. Long exposure is an engineering achievement. A durable improvement in health would require its own outcome data.
Sermorelin supplies a useful reversal of perspective. The peptide disappeared rapidly in a healthy-men experiment, yet growth hormone stayed elevated for about three hours. The molecule’s lifetime and the response’s lifetime were already different.
Ipamorelin complicates any simple story about fat loss. In ferrets exposed to chemotherapy, it reduced delayed-phase weight loss without reducing vomiting. Preserving weight was the desired direction in that animal model. The endpoint changes the meaning of an effect.